<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03488901</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_807</org_study_id>
    <nct_id>NCT03488901</nct_id>
  </id_info>
  <brief_title>Chemoresistance of Trophoblastic Tumors</brief_title>
  <acronym>PrediCTTro</acronym>
  <official_title>Prediction of Chemoresistance in Patients Treated for Gestational Trophoblastic Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gestational trophoblastic tumors are characterized by their development from placental tissue
      and their high invasive and metastatic potential. These are rare tumors (1/50 000
      pregnancies) affecting young women for whom conservative fertility treatments are preferred.
      The therapeutic strategy is based on a chemotherapy whose choice of protocol is based on a
      clinico-biological score, FIGO score, which includes tumor size, gonadotropic chorionic
      hormone level used as quantitative tumor marker, number and localization. metastases. A FIGO
      score ≤6 allows the use of monochemotherapy (methotrexate) with a 5-year survival of
      approximately 99.7%. Scores of 7 to 12 and ≥13 require multidrug therapy (EMA-CO) and are
      associated with 5-year survival of 95.1% and 61.6%, respectively.

      The chemotherapies currently used for the treatment of trophoblastic tumors have been
      described between the 1950s (methotrexate) and the 1980s (EMA-CO) and have a well documented
      toxicity regarding the risk of secondary tumors, early menopause or even death by toxicity. .

      To date, apart from the FIGO score, there is no predictor of resistance to chemotherapy in
      gestational trophoblastic tumors. However, among patients with a FIGO score ≤6 and receiving
      methotrexate in the first line, 9 to 46% will have a resistance and require a second line of
      treatment. Similarly, if the score is ≥7, 10 to 30% of patients receiving EMA-CO will require
      at least a second line of multidrug therapy.

      The hypothesis of PrediCTTro study is that tissue samples of gestational choriocarcinoma
      present a transcriptomic profile associated with the risk of further resistance to single or
      multiagent chemotherapy.

      The objective of PrediCTTro is to identify a transcriptomic signature able to predict
      resistance to single or multiagent chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Transcription profile associated with the resistance to chemotherapy</measure>
    <time_frame>10 months</time_frame>
    <description>The expression level of 800 genes involved in oncogenesis canonical pathways and immune tolerance will be assessed and correlated with the resistance to single or multiagent chemotherapy.</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Trophoblastic Tumor</condition>
  <arm_group>
    <arm_group_label>methotrexate sensitive</arm_group_label>
    <description>patients with gestational choriocarcinoma cured with methotrexate alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methotrexate resistant</arm_group_label>
    <description>patients with gestational choriocarcinoma not cured with methotrexate alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>polychemotherapy sensitive</arm_group_label>
    <description>patients with gestational choriocarcinoma cured with polychemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>polychemotherapy resistant</arm_group_label>
    <description>patients with gestational choriocarcinoma not cured with polychemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hydatidiform moles without malignant transformation</arm_group_label>
    <description>patients treated for hydatidiform moles but who did not turn into trophoblastic tumors (=controls)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placental site trophoblastic tumors</arm_group_label>
    <description>patients with placental site trophoblastic tumors not cured with polychemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>chemoresistance signature</intervention_name>
    <description>to study the predictive value of a tissue transcriptomic profile (=chemoresistance signature) in the chemoresistance to single or multiagent chemotherapy</description>
    <arm_group_label>methotrexate sensitive</arm_group_label>
    <arm_group_label>methotrexate resistant</arm_group_label>
    <arm_group_label>polychemotherapy sensitive</arm_group_label>
    <arm_group_label>polychemotherapy resistant</arm_group_label>
    <arm_group_label>hydatidiform moles without malignant transformation</arm_group_label>
    <arm_group_label>placental site trophoblastic tumors</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Formalin fixed and paraffin embedded tissue samples of gestational choriocarcinoma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with gestational trophoblastic tumors
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed gestational trophoblastic tumor histology

          -  hCG follow-up of at least 12 months after hCG normalization

          -  registration in the French Reference Center for Trophoblastic Diseases

        Exclusion Criteria:

          -  tissue specimen (block/biopsy) not available

          -  degraded quality of tissue sample not compatible with transcriptome analysis (&gt;20% of
             necrosis)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Pierre-Adrien BOLZE, Dr</last_name>
    <phone>04 78 86 56 40</phone>
    <phone_ext>+33</phone_ext>
    <email>pierre-adrien.bolze@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>François GOLFIER, Pr</last_name>
    <phone>04 78 86 66 78</phone>
    <phone_ext>+33</phone_ext>
    <email>francois.golfier@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Français de Référence des Maladies Trophoblastiques</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Adrien BOLZE, Dr</last_name>
      <phone>04 78 86 56 40</phone>
      <phone_ext>+33</phone_ext>
      <email>pierre-adrien.bolze@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>François GOLFIER, Pr</last_name>
      <phone>04 78 86 66 78</phone>
      <phone_ext>+33</phone_ext>
      <email>francois.golfier@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>March 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trophoblastic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

